UNSPSC 51142525: Droxidopa

This classification denotes an antiparkinsonian agent with the molecular formula C9H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J7A92W69L7, chemically known as (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine but generally known as droxidopa, which bears US NIH Compound Identifier 3171. European Medicines Agency schedules Droxidopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06420MIG.

UNSPSC 51142525 Droxidopa is a Commodity code that nominally designates a single pharmaceutical product, but recent state and local activity shows the code is being used to solicit a broader range of pharmaceuticals and drug-related products. Seminole County, Florida recently sought Naloxone and drug deactivation systems through an IFB, while Texas HHS and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted opportunities for generic multi-source pharmaceuticals and over-the-counter products more broadly. State and local buyers are using this code for pharmaceutical procurement ranging from specialized medications like naloxone to comprehensive generic drug catalogs and OTC inventory for health systems, correctional facilities, and community health programs. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions and state and local facilities.

Recent activity appears concentrated in Texas, Minnesota (through MMCAP, which serves multiple states including Oregon), and Florida. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the county community health building. Texas HHS issued an RFI (HHS0017013) on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs without a formal evaluation timeline. MMCAP posted RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) effective July 1, 2026. MMCAP's procurement weighted price competitiveness at 75 percent and required vendor compliance with cGMP, DSCSA, and FDA requirements, with a 3 percent administrative fee on all contract purchases.